Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 7;48(7-8):367-371.
doi: 10.14745/ccdr.v48i78a09.

Summary of the National Advisory Committee on Immunization (NACI) Rapid Response-Interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada

April Killikelly  1 , Nicholas Brousseau  2
Affiliations

Summary of the National Advisory Committee on Immunization (NACI) Rapid Response-Interim guidance on the use of Imvamune in the context of monkeypox outbreaks in Canada

April Killikelly et al. Can Commun Dis Rep. .

Abstract

Background: Monkeypox is endemic in Central and West Africa. Cases in non-endemic countries, including Canada, have been increasing since May 2022. Imvamune®, a live, non-replicating smallpox vaccine, was approved by Health Canada for active immunization against smallpox and monkeypox infections and disease in adults determined to be at high risk for exposure. The aim of this interim guidance is to consider the use of Imvamune for post-exposure prophylaxis (PEP) and to summarize the available evidence in support of Imvamune use in this specific current context.

Methods: The National Advisory Committee on Immunization (NACI) High Consequence Infectious Disease Working Group (HCID WG) reviewed data on the current status of the monkeypox outbreak, along with additional evidence included in published scientific literature and from manufacturers, regarding the safety, immunogenicity and protection offered by Imvamune. NACI approved these HCID WG recommendations on June 8, 2022.

Results: In brief, NACI recommends that PEP, using a single dose of the Imvamune vaccine, may be offered to individuals with high-risk exposures to a probable or confirmed case of monkeypox, or within a setting where transmission is happening. After 28 days, if an individual is assessed as having a predictable ongoing risk of exposure, a second dose may be offered. Imvamune may be offered to special populations; including individuals who are immunosuppressed, pregnant, breastfeeding, younger than 18 years of age and/or with atopic dermatitis.

Conclusion: NACI has rapidly developed guidance on the use of Imvamune in Canada in the context of many uncertainties. Recommendations may be revisited as new evidence emerges.

Keywords: Canada; Imvamune interim guidance; National Advisory Committee on Immunization; monkeypox.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None.

References

    1. Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, Osborne JC, Rampling T, Beadsworth MB, Duncan CJ, Dunning J, Fletcher TE, Hunter ER, Jacobs M, Khoo SH, Newsholme W, Porter D, Porter RJ, Ratcliffe L, Schmid ML, Semple MG, Tunbridge AJ, Wingfield T, Price NM; NHS England High Consequence Infectious Diseases (Airborne) Network. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis 2022;22(8):1153–62. 10.1016/S1473-3099(22)00228-6 - DOI - PMC - PubMed
    1. Mbala PK, Huggins JW, Riu-Rovira T, Ahuka SM, Mulembakani P, Rimoin AW, Martin JW, Muyembe JT. Maternal and Fetal Outcomes Among Pregnant Women With Human Monkeypox Infection in the Democratic Republic of Congo. J Infect Dis 2017;216(7):824–8. 10.1093/infdis/jix260 - DOI - PubMed
    1. Product Monograph, including patient medication information. Imvamune®. https://pdf.hres.ca/dpd_pm/00058622.PDF
    1. Verheust C, Goossens M, Pauwels K, Breyer D. Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination. Vaccine 2012;30(16):2623–32. 10.1016/j.vaccine.2012.02.016 - DOI - PubMed
    1. Public Health Agency of Canada. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). NACI Rapid Response - Interim guidance on the use of Imvamune® in the context of monkeypox outbreaks in Canada. Ottawa, ON: PHAC. https://www.canada.ca/content/dam/phac-aspc/documents/services/immunizat...